Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Parallel Bio
Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune…
Parallel Bio
Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune…
TL;DR
Founded: 2021
Headquarters: Cambridge, Massachusetts
Core technology: Human immune organoids + AI and automation
Total disclosed funding: ≈ $25.6M (across pre-seed, seed, Series A)
Notable investors: Y Combinator; AIX Ventures; Refactor; Jeff Dean
Company Overview
Problem Domain
Preclinical prediction for immunotherapy discovery; reducing drug failure rates due to poor translatability from animal models to humans.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre-seed round recorded in 2021
Seed round recorded Dec 20, 2022
21000000
Series A reported June 2025 (~$21M)
Investor Signal
“Includes participation from Y Combinator and a mix of venture firms and individual/backing investors (examples reported: AIX Ventures, Refactor, Jeff Dean)”
